We focused our attention on the FASN gene, the central metabolic multifunctional enzyme involved in “de novo” biosynthesis of FAs, because of its overexpression and hyperactivity in most human malignancies and the extensive literature already reported in HER2+ BC models [20–29]. The gene discussed is ERBB2; the disease is breast cancer.